
Opinion|Videos|November 29, 2024
Case 3: Persistently Active Central Retinal Vein Occlusion
Key Takeaways
In the third case, moderator Lisa J. Faia, MD presents her case of persistently active central retinal vein occlusion (CRVO), explaining her approach to switching this treatment-resistant patient to a newer agent.
Advertisement
Episodes in this series

Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
2
PainReform launches development plan for OcuRing-K, readies phase 2 trial
3
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
4
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
5















































.png)


